Page 46 - Read Online

Sooi et al. Cancer Drug Resist 2023;6:656-73 https://dx.doi.org/10.20517/cdr.2023.48 Page 662

NCT03061539 2 Ipilimumab + Nivolumab mCRPC with immunogenic ORR, PSA response Active, not
signature after progression on 1 recruiting
systemic therapy
NCT02985957 2 Ipilimumab + Nivolumab mCRPC ORR, rPFS Active, not
Ipilimumab recruiting
Cabazitaxel
NCT03333616 2 Ipilimumab + Nivolumab Non-adenocarcinoma PC ORR Active,
recruiting
NCT02788773 2 Durvalumab + Tremelimumab mCRPC with prior exposure to 1 ORR Active, not
NHA recruiting
ICIs + androgen receptor antagonist
NCT03016312 3 Atezolizumab + Enzalutamide mCRPC with prior exposure to 1 OS Completed
Enzalutamide NHA and 1 chemotherapy
NCT02787005 2 Pembrolizumab + Enzalutamide mCRPC progressing on ORR Completed
Enzalutamide
NCT04191096 3 Pembrolizumab + Enzalutamide mHSPC rPFS, OS Active, not
Enzalutamide recruiting
NCT03834493 3 Pembrolizumab + Enzalutamide mCRPC, allows for prior rPFS, OS Active, not
Enzalutamide Abiraterone exposure recruiting
NCT02312557 2 Pembrolizumab + Enzalutamide mCRPC after progression on PSA response Active, not
Enzalutamide recruiting
NCT03338790 2 Nivolumab + Rucaparib mCRPC ORR, PSA response Active, not
Nivolumab + Docetaxel recruiting
Nivolumab + Enzalutamide
NCT01688492 1/2 Ipilimumab + Abiraterone mCRPC Safety, PFS Active, not
recruiting
ICIs + chemotherapy
NCT03338790 2 Nivolumab + Docetaxel mCRPC ORR, PSA response Active, not
recruiting
NCT04100018 3 Nivolumab + Docetaxel mCRPC after progression on 1-2 rPFS, OS Active,
Nivolumab NHAs recruiting
NCT03834506 3 Pembrolizumab + Docetaxel mCRPC with prior exposure to 1 rPFS, OS Active, not
Docetaxel NHA recruiting
NCT02861573 1/2 Pembrolizumab + Docetaxel mCRPC ORR, safety, PSA Active,
Multiple cohorts response recruiting
NCT03409458 1/2 Avelumab + PT-112 (Platinum + mCRPC Safety, PSA response Active, not
Pyrophosphate ligand) recruiting
NCT02601014 2 Nivolumab + Ipilimumab AR-V7-expressing mCRPC PSA response Completed
NCT02788773 2 Durvalumab + Tremelimumab mCRPC with prior exposure to 1 ORR Active, not
Durvalumab NHA recruiting
ICIs + radiopharmaceuticals
NCT02814669 1 Atezolizumab + Radium-223 mCRPC after progression on 1 ORR, safety Completed
NHA and 1 chemotherapy
NCT04109729 1/2 Nivolumab + Radium-223 mCRPC with symptomatic bone Safety, ctDNA Active,
metastases reduction recruiting
NCT03658447 1/2 Pembrolizumab + 177Lu-PSMA mCRPC after progression on 1 Safety, PSA response Completed
NHA

CBR: Clinical benefit rate; CRPC: castration-resistant prostate cancer; DCR: disease control rate; DLT: dose limiting toxicity; DOR: duration of
response; ICIs: immune checkpoint inhibitors; mCRPC: metastatic castration-resistant prostate cancer; mPC: metastatic prostate cancer; NHA:
novel hormonal agent; ORR: objective response rate; OS: overall survival; PARP: poly(ADP)-ribose polymerase; PC: prostate cancer; PFS:
progression-free survival; PSA: prostate-specific antigen; rPFS: radiologic progression-free survival; RT: radionuclide therapy.

Sipuleucel-T is a therapeutic dendritic cell-based vaccine that has received FDA approval for use in the
treatment of patients with asymptomatic or minimally symptomatic mCRPC, based on overall survival (OS)